Cancer Stem Cell News Volume 3.46 | Nov 26 2014

Mitochondria as New Therapeutic Targets for Eradicating Cancer Stem Cells: Quantitative Proteomics and Functional Validation via MCT1/2 Inhibition
Researchers used quantitative proteomics analysis to identify novel therapeutic targets in cancer stem cells and/or progenitor cells. For this purpose, mammospheres from two ER-positive breast cancer cell lines were grown in suspension using low-attachment plates and directly compared to attached monolayer cells grown in parallel. [Oncotarget] Full Article | Press Release

Systematic Identification of Single Amino Acid Variants in Glioma Stem-Cell-Derived Chromosome 19 Proteins
Novel proteoforms with single amino acid variations represent proteins that often have altered biological functions but are less explored in the human proteome. Scientists developed an approach, searching high quality shotgun proteomic data against an extended protein database, to identify expressed mutant proteoforms in glioma stem cell lines. [J Proteome Res] Abstract | Graphical Abstract

Active Targeting Docetaxel-PLA Nanoparticles Eradicate the Circulating Lung Cancer Stem Like Cells and Inhibit the Liver Metastasis
Researchers aimed to establish a cancer stem cells (CSCs)-targeting polylactic acid encapsulated docetaxel nanoparticles for anti-metastatic therapy. Cyclic binding peptides were screened on CSCs in vitro and the peptide CVKTPAQSC exhibiting high specific binding ability to pulmonary adenocarcinoma tissue was subsequently conjugated to the nanoparticles loaded with docetaxel. [Mol Pharm] Abstract

Nitric Oxide Induces Cancer Stem Cell-Like Phenotypes in Human Lung Cancer Cells
Researchers show how nitric oxide, a key cellular modulator whose level is elevated in many tumors, affects cancer stem cell-like phenotypes of human non-small-cell lung carcinoma H292 and H460 cells. [Am J Physiol Cell Physiol] Abstract

TRIM28 and β-Actin Identified via Nanobody-Based Reverse Proteomics Approach as Possible Human Glioblastoma Biomarkers
Scientists immunized an alpaca with a human glioblastoma multiforme (GBM) stem-like cell line prepared from primary GBM cultures. Next, a nanobody library was constructed in a phage-display vector. Using nanobody phage-display technology they selected specific GBM stem-like cell binders through a number of affinity selections. [PLoS One] Full Article

Overexpression of miR-200a Suppresses Epithelial-Mesenchymal Transition of Liver Cancer Stem Cells
Researchers investigated the role of miR-200a in regulation of epithelial-mesenchymal transition phenotype of liver cancer stem cells (LCSCs). They used side population (SP) sorting to obtain cancer stem-like cells from hepatocellular carcinoma cell lines and identified that the SP fraction could be enriched with LCSCs. [Tumour Biol] Abstract

Prognostic Relevance of Carbonic Anhydrase IX Expression Is Distinct in Various Subtypes of Breast Cancer and Its Silencing Suppresses Self-Renewal Capacity of Breast Cancer Cells
Scientists elucidated the prognostic significance of carbonic anhydrase IX (CAIX) in the intrinsic subtypes of breast cancer and to characterize CAIX as a drug target in breast cancer. [Cancer Chemother Pharmacol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (Nivolumab) and FPA008 in Six Tumor Types
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo, Bristol-Myers Squibb’s investigational programmed death-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor. [Bristol-Myers Squibb Company] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Energy Metabolism and Nutrient Sensing in Cancer Development and Stem Cells (MD Anderson Cancer Center)

Postdoctoral Fellow – Cancer Biology (Lund University)

Postdoctoral Position – Intestinal Stem Cell Biology and Gastrointestinal Malignancies (Albert Einstein College of Medicine of Yeshiva University)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Postdoctoral Position – Leukemic Stem Cells (BC Cancer Agency)

Assistant or Associate Professor – Cancer Biology (University of Pennsylvania)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.